CYPHERPUNK TECHNOLOGIES INC. (CYPH): Results of Operations and Financial Condition
CYPHERPUNK TECHNOLOGIES INC. (CYPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cypherpunk Technologies Reports Second Quarter 2026 Financial Results Cambridge, Mass. – August 12, 2026 – Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quarter ended June 30, 2026. "In the second quarter
How this was made
The 30-second read
Why it matters
Traders can reassess near-term earnings quality (ZEC mark-to-market) and the probability-weighted path to registrational development (FDA Type C alignment, Fast Track, and a biomarker-selected Phase 3 design). The strategic review for sirexatamab introduces uncertainty around financing and deal timing.
Market read
This is a primary 8-K with both financials and concrete clinical/regulatory pathway details, likely to drive trading around earnings optics and biotech development expectations.
What to watch
The strategic process for sirexatamab (spin-out vs partner) is not time-bound, and the article does not quantify cash runway or dilution risk, which can dominate valuation despite FDA feedback.
Cypherpunk Technologies Reports Second Quarter 2026 Financial Results
Net income of $39.4 million was driven primarily by a $46.0 million unrealized gain on ZEC treasury holdings, while research and development expense declined materially and general and administrative expense increased.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net incomeGAAP | $39.4 million | – | – |
| Diluted earnings per shareGAAP | $0.18 per diluted share | – | – |
| Research and development expensesGAAP | $0.2 million | – | – |
| General and administrative expensesGAAP | $4.5 million | – | increase of $2.7 million |
| Unrealized gain on change in fair value of ZEC treasury holdingsGAAP | $46.0 million | – | – |
| Cash and cash equivalentsother | $7.6 million | – | – |
| ZEC treasury holdings, categorized as digital asset receivableother | $129.4 million | – | – |
What drove it
- Net income was primarily due to a $46.0 million unrealized gain on the fair value of ZEC treasury holdings during the second quarter of 2026.
- During the second quarter of 2026, the price of ZEC increased from $243.35 to $400.09.
- Research and development expenses decreased primarily due to decreased clinical trial and manufacturing expenses following completion of clinical trials, together with lower payroll and related expenses associated with the 2025 reduction in force.
- General and administrative expenses increased primarily due to a $1.7 million increase in stock-based compensation, a $0.8 million increase in payroll and related expenses, and a $0.2 million increase in professional fees.
- Leap Therapeutics reached FDA alignment on a proposed randomized, controlled Phase 3 trial for sirexatamab in DKK1-high, second-line metastatic colorectal cancer.
Concerns
- The reported net income was primarily driven by an unrealized gain on ZEC holdings that are marked to market at the end of each period.
- The Company identifies the highly volatile nature of the price of ZEC as a risk and states that decreases in the price of ZEC may result in unrealized losses and net loss.
- Leap's prespecified primary endpoint was not met in the intent-to-treat population in the Phase 2 DeFianCe study.
- There can be no assurance that Leap's strategic process will result in a transaction or financing, or that any completed transaction or financing will be on favorable terms.
What to watch
- Changes in the price of ZEC and their effect on the fair value of the Company's ZEC treasury holdings and financial statements.
- Progress of Leap's strategic process to secure resources for Phase 3 development of sirexatamab.
- Advancement of the proposed Phase 3 sirexatamab trial, including objective response rate in an initial group of approximately 160 patients and overall survival in the full study population.
- Development of a blood-based companion diagnostic to identify DKK1-high patients in routine clinical practice.
Balance sheet and cash flow
- Cash and cash equivalents totaled $7.6 million on June 30, 2026.
- ZEC treasury holdings, categorized as digital asset receivable, totaled $129.4 million based on the ZEC price of $400.09 on June 30, 2026.
- As of August 11, 2026, Cypherpunk held a total of 323,394.38 ZEC at an average purchase price of $341.83, representing approximately 1.92% of the total circulating supply of the Zcash network.
Analysis
Cypherpunk reported net income of $39.4 million, or $0.18 per diluted share, compared with a net loss of $16.6 million in the second quarter of 2025. The release identifies a $46.0 million unrealized gain on the fair value of ZEC treasury holdings as the primary driver of the result. ZEC increased from $243.35 to $400.09 during the second quarter of 2026, making reported earnings directly sensitive to the mark-to-market value of the treasury position.
The expense profile changed substantially. Research and development expenses were $0.2 million, compared with $10.5 million for the same period in 2025, following completion of clinical trials and lower payroll and related expenses associated with the 2025 reduction in force. General and administrative expenses rose to $4.5 million from $1.8 million, led by a $1.7 million increase in stock-based compensation, a $0.8 million increase in payroll and related expenses, and a $0.2 million increase in professional fees.
Treasury strategy remains central to the financial profile. Cash and cash equivalents totaled $7.6 million on June 30, 2026, while ZEC treasury holdings categorized as digital asset receivable totaled $129.4 million based on a ZEC price of $400.09. As of August 11, 2026, the Company held 323,394.38 ZEC at an average purchase price of $341.83, representing approximately 1.92% of the total circulating supply of the Zcash network. The release also explicitly identifies ZEC price volatility and potential unrealized losses as risks.
At Leap Therapeutics, the Company reported FDA alignment on key elements of a proposed Phase 3 trial for sirexatamab in DKK1-high, second-line metastatic colorectal cancer. The planned study is expected to enroll approximately 270 patients, with objective response rate in an initial group of approximately 160 patients potentially supporting accelerated approval and overall survival in the full study population intended to support full approval. However, the Phase 2 DeFianCe study did not meet its prespecified primary endpoint in the intent-to-treat population, and Leap has initiated a strategic process to determine whether to finance the program independently or pursue a transaction.
No forward financial guidance was provided. The principal operating milestones are the outcome of Leap's strategic process, advancement of the proposed Phase 3 program and companion diagnostic, and movements in ZEC, which materially affect the carrying value of the treasury holdings and reported earnings.
Management, verbatim
In the second quarter, Cypherpunk built upon the momentum established earlier this year through the disciplined execution of our Zcash digital asset treasury strategy, increasing our treasury holdings to 323,394.38 ZEC, and welcoming Dev Ojha, founder of Valar Group, as an Advisor.
Douglas E. Onsi, President and CEO of Cypherpunk Technologies
Our Leap Therapeutics subsidiary reached alignment with the FDA on a proposed Phase 3 trial in a DKK1-high, second-line, metastatic colorectal cancer population, with objective response rate as the primary endpoint to support accelerated approval and overall survival to support full approval in the United States and registration globally.
Douglas E. Onsi, President and CEO of Cypherpunk Technologies
Our execution in the second quarter reinforces Cypherpunk’s conviction in Zcash as a foundational monetary asset.
Will McEvoy, Chief Investment Officer of Cypherpunk
Not in the filing
stated, not guessed- Total revenue
- Revenue comparisons and revenue growth
- Segment revenue and segment comparisons
- Gross profit and gross margin
- Operating income or loss and operating margin
- Non-GAAP financial measures, including non-GAAP net income and non-GAAP EPS
- Prior-year diluted earnings per share
- Prior-quarter financial metrics
- Operating cash flow
- Free cash flow
- Debt
- Share repurchases
- Dividends
- Tax rate
- Forward financial guidance
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Cypherpunk’s 8-K (Item 2.02) reports Q2 2026 financial results and includes an EX-99.1 with updates from its Zcash treasury strategy and its Leap Therapeutics subsidiary’s oncology development.
Ticker impact
Cypherpunk reported Q2 results and disclosed ZEC treasury growth to 323,394.38 ZEC, plus Leap’s FDA-aligned Phase 3 plan for sirexatamab.
Near-term volatility risk tied to ZEC mark-to-market, with upside bias if traders focus on FDA alignment and Fast Track/Phase 3 registrational design.
The 8-K is a primary disclosure (Q2 financials plus FDA Type C alignment and Phase 3 design details). However, the article does not provide guidance, cash balance, or explicit probability-weighted outcomes, limiting precision on equity impact.
Market effects
Adds a datapoint on how crypto treasury mark-to-market can drive biotech-like earnings optics for privacy/crypto-adjacent issuers.
Limited, primarily US-listed small-cap sentiment and risk appetite for crypto-treasury equities.
Moderate, as the clinical program targets US accelerated approval and global registration, but no new global regulatory actions were disclosed.
Counterpoint
The headline clinical progress may not translate into near-term value without financing clarity, and the reported net income is heavily influenced by unrealized ZEC gains.
Key entities
- issuerCypherpunk Technologies Inc.
Nasdaq-listed company reporting Q2 2026 results and ZEC treasury holdings growth, plus subsidiary updates.
- subsidiaryLeap Therapeutics
Company within Cypherpunk developing sirexatamab for DKK1-high metastatic colorectal cancer.
- drug_programsirexatamab (DKN-01)
Anti-DKK1 monoclonal antibody with Phase 2 DeFianCe publication and FDA-aligned Phase 3 registrational plan.
- regulatorFDA
Provided feedback via a Type C meeting supporting key Phase 3 design elements and biomarker-selected population.
- crypto_assetZcash (ZEC)
Digital asset held in Cypherpunk’s treasury; Q2 results cite a large unrealized gain driven by ZEC price appreciation.
